Member Info for Jarv55

Sellers cleared brakes are coming off at last https://invst.ly/sp6yq

tom why do you keep putting hands Face space?

back up she goes https://invst.ly/sp488

Remmeber when they dropped ncyt dowm from 2.20 to 0.85 then back up again they are doing a spring here, strap in folks just remember contracts and revenue, mms will try every trick in the book. Warrants are getting flushed.
https://invst.ly/sp3pm

third step being built https://invst.ly/sp31u

Disagree the herd is not here yet when it hits the papers then you will see the herd

This could easily reach a 200mc on contracts

https://www.iso.org/standard/71292.html

Its already estabilished POC
The Board of Remote Monitored Systems plc ("the Company") notes the following announcement published by Braveheart Investment Group ("Braveheart") today in respect of Pharm 2 Farm Limited ("P2F"). As announced on 21 August 2020, RMS has signed a binding Share Purchase Agreement for the acquisition of 100% of the share capital of P2F (the "Acquisition"). Completion of the Acquisition remains subject to RMS shareholder approval, details of which were announced on 19 October 2020. The full text of the Braveheart announcement is set out below.



"Braveheart Investment Group (AIM: BRH) provides an update on progress with the Pharm2Farm Limited ("P2F") anti-viral surgical mask project.

P2F has developed a coating for textiles which incorporates its proprietary nanoparticles to give textiles long lasting virucidal properties. The first application of this technology has been to coat a fabric layer in surgical masks and produce a certified antiviral (including COVID-19 and Influenza) mask for use by both healthcare professionals and the public.

P2F has now overcome the delay in testing, reported on 8 October 2020, by conducting live virus tests at two independent UK laboratories. These tests confirmed that the coated face mask textile displayed high virucidal activity, meeting the requirements for ISO 18184 certification with more than a 90% kill rate for up to 7 hours, while being benign to healthy mammalian cells (ISO 18184 is the international anti-viral textile standard that measures virucidal antimicrobial activity on textiles and other porous materials).

The manufacturing process for this new formulation, along with its antiviral, antibacterial and antiparasitic properties has now been submitted as a patent application by P2F to protect its intellectual property.

As previously announced on 18 September 2020, P2F has purchased an automated mask production line, which is on track to be delivered in November 2020 and to be commissioned by the end of December 2020. The production line, which is manufactured in Europe, has the capacity to produce up to five million standard or anti-viral face masks per month.

Following this positive test result, P2F plans to produce anti-COVID-19 surgical face masks certified to ISO 18184 for sale by the end of this year.

02-Nov-20 16:07:12 4.56001 362,552 Buy* 4.40 4.50 16.53k O
02-Nov-20 15:56:58 4.455 430,884 Buy* 4.40 4.50 19.20k O
02-Nov-20 15:40:29 4.50 390,000 Buy* 4.40 4.50 17.55k O
02-Nov-20 15:40:29 4.50 390,000 Buy* 4.40 4.50 17.55k O
02-Nov-20 15:34:00 4.46 350,000 Buy* 4.40 4.50 15.61k O
02-Nov-20 16:28:35 4.43 202,135 Sell* 4.40 4.50 8,955 O
02-Nov-20 16:26:34 4.5375 165,013 Buy* 4.40 4.50 7,487 O
02-Nov-20 16:26:05 4.50 154,356 Buy* 4.40 4.50 6,946 O
02-Nov-20 16:24:31 4.58 150,000 Buy* 4.40 4.50 6,870 O
02-Nov-20 15:22:33 4.619 380,000 Buy* 4.40 4.50 17.55k O
02-Nov-20 16:19:26 4.60 150,000 Buy* 4.40 4.50 6,900 O
02-Nov-20 15:17:41 4.677 380,000 Buy* 4.40 4.50 17.77k O
02-Nov-20 16:15:02 4.505 174,895 Buy* 4.40 4.50 7,879 O
30-Oct-20 12:56:45 3.2703 850,000 Sell* 4.40 4.50 27.80k O
30-Oct-20 08:45:25 3.30 700,000 Sell* 4.40 4.50 23.10k O
30-Oct-20 08:11:21 3.25 1,000,000 Sell* 4.40 4.50 32.50k O
30-Oct-20 12:47:04 3.26 746,472 Sell* 4.40 4.50 24.33k O
30-Oct-20 10:39:19 3.181 692,014 Sell* 4.40 4.50 22.01k O
30-Oct-20 08:20:04 2.95 900,000 Sell* 4.40 4.50 26.55k O
30-Oct-20 14:00:36 3.60 1,000,000 Sell* 4.40 4.50 36.00k O
30-Oct-20 16:26:35 3.26 979,412 Sell* 4.40 4.50 31.93k O
30-Oct-20 14:12:07 3.53 1,000,000 Sell* 4.40 4.50 35.30k O
30-Oct-20 08:07:37 3.0949 1,615,562 Sell* 4.40 4.50 50.00k O
30-Oct-20 15:36:17 3.32 746,472 Sell* 4.40 4.50 24.78k O
30-Oct-20 12:48:12 3.1152 904,000 Sell* 4.40 4.50 28.16k O
30-Oct-20 08:13:08 3.11 900,000 Sell* 4.40 4.50 27.99k O
30-Oct-20 12:33:11 3.20 1,170,851 Sell* 4.40 4.50 37.47k O
30-Oct-20 08:43:51 3.25 750,000 Sell* 4.40 4.50 24.38k O
30-Oct-20 08:22:27 3.00 900,000 Sell* 4.40 4.50 27.00k O
30-Oct-20 10:14:29 3.1575 785,853 Sell* 4.40 4.50 24.81k O
30-Oct-20 08:24:38 3.0359 1,011,679 Sell* 4.40 4.50 30.71k O
02-Nov-20 16:09:09 4.60 250,000 Buy* 4.40 4.50 11.50k O
02-Nov-20 16:04:43 4.675 213,903 Buy* 4.40 4.50 10,000 O
02-Nov-20 16:03:35 4.677 200,000 Buy* 4.40 4.50 9,354 O
02-Nov-20 15:59:54 4.59 150,000 Buy* 4.40 4.50 6,885 O
02-Nov-20 15:59:35 4.575 218,371 Buy* 4.40 4.50 9,990 O
02-Nov-20 15:59:11 4.575 143,737 Buy* 4.40 4.50 6,576 O
02-Nov-20 15:48:12 4.49 187,082 Buy* 4.40 4.50 8,400 O
02-Nov-20 15:46:46 4.42001 154,039 Sell* 4.40 4.50 6,809 O
30-Oct-20 14:05:22 3.80 97,000 Sell* 4.40 4.50 3,686 O
30-Oct-20 14:05:22 3.80 -97,000 Sell* 4.40 4.50 -3,686 O

games being played look at those delayed trades

Any new contracts and the chart goes out the window.

P2F has received a conditional order for 1 million face masks per month for a period of one year from 1 January 2021. This order is subject to contract and conditional on the masks successfully completing antiviral and other performance tests and receiving the necessary PPE certifications. The order is also conditional on the buyer entering into sales contracts to sell a similar volume of masks per month.

In readiness for commercial release, P2F will shortly make a patent application to protect its technology for producing the antiviral material, which it is confident could be applied to air filters, face masks and other PPE.

Elsewhere in its operations, P2F has now completed the initial trial of its proprietary zinc nanotechnology, with positive results, at a citrus farm in the UK. P2F will commence trials in the USA shortly and if success is replicated in the USA trials, it expects to launch this product in early 2021, for farmers to apply during the 2021 growing season. The product is part of the company's nSitu™ range of nano-agritech materials, designed to support commercial farmers around the world - in this case by helping to protect the USA's annual 8 million tons of citrus fruit crops, with an estimated value of such crops of over $3.3 billion."

Further to the announcement of 19 October 2020, Braveheart notes that the conditional sale of its 51.72% holding in Pharm 2 Farm Limited to Remote Monitored Systems plc ("RMS") is expected to complete on 5 November 2020 (the "Sale"). The Sale is subject to, amongst other things, the passing of the resolutions, including the resolution seeking approval of the whitewash of Braveheart's Rule 9 obligations by the independent shareholders of RMS, at the General Meeting of RMS being held on 4 November 2020.

Following the completion of the Sale, Braveheart will hold 509,992,405 Ordinary Shares of 0.01p each in RMS, representing 37.12 per cent of the enlarged share capital of RMS."

"Braveheart Investment Group (AIM: BRH) provides an update on progress with the Pharm2Farm Limited ("P2F") anti-viral surgical mask project.

P2F has developed a coating for textiles which incorporates its proprietary nanoparticles to give textiles long lasting virucidal properties. The first application of this technology has been to coat a fabric layer in surgical masks and produce a certified antiviral (including COVID-19 and Influenza) mask for use by both healthcare professionals and the public.

P2F has now overcome the delay in testing, reported on 8 October 2020, by conducting live virus tests at two independent UK laboratories. These tests confirmed that the coated face mask textile displayed high virucidal activity, meeting the requirements for ISO 18184 certification with more than a 90% kill rate for up to 7 hours, while being benign to healthy mammalian cells (ISO 18184 is the international anti-viral textile standard that measures virucidal antimicrobial activity on textiles and other porous materials).

The manufacturing process for this new formulation, along with its antiviral, antibacterial and antiparasitic properties has now been submitted as a patent application by P2F to protect its intellectual property.

As previously announced on 18 September 2020, P2F has purchased an automated mask production line, which is on track to be delivered in November 2020 and to be commissioned by the end of December 2020. The production line, which is manufactured in Europe, has the capacity to produce up to five million standard or anti-viral face masks per month.

Following this positive test result, P2F plans to produce anti-COVID-19 surgical face masks certified to ISO 18184 for sale by the end of this year.

they had the speeding ticket last week there won't be another

Worth a listen cannabis side is interesting https://www.youtube.com/watch?v=22pS6R78DUI

Hold tight people https://twitter.com/Jarvy55/status/1323213382539972619

Can see this breaking 4p this afternoon https://invst.ly/soho8

Listen very carefully also going into the flu market
https://www.youtube.com/watch?v=rtewviIlIUw&t=405s

croyx I think profits will be around 30p per mask listen to the interview costs are say 10p to produce the tech adds more value.